Uveal Melanoma

Adjuvant Quisinostat in High-Risk Uveal Melanoma – NCT06932757

Quisinostat for High-Risk Uveal Melanoma Phase: Phase 2Trial ID: NCT06932757Treatment: QuisinostatStage: High-risk uveal melanoma following treatment of the primary eye tumour, with no evidence that the cancer has spreadLocation: United States – University of Miami, Florida What is this trial looking at? This Phase 2 study is investigating whether a drug called quisinostat can reduce or delay the risk of uveal […]

Adjuvant Quisinostat in High-Risk Uveal Melanoma – NCT06932757 Read More »

A Randomized, Phase 2/​3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma – NCT06581406

REVEAL – RP2 + Nivolumab for Metastatic Uveal Melanoma Phase: Phase 2/3Trial ID: NCT06581406 / RP2-202Treatment: RP2 + nivolumab compared with ipilimumab + nivolumabStage: Metastatic uveal melanomaUK locations: The Royal Marsden, London and The Clatterbridge Cancer Centre, LiverpoolStatus: Recruiting What is this trial looking at? The REVEAL study is investigating a new type of immunotherapy called RP2, given together with nivolumab, for

A Randomized, Phase 2/​3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma – NCT06581406 Read More »

Neoadjuvant Darovasertib in Primary Uveal Melanoma – NCT07015190

OptimUM-10 – Darovasertib before treatment for primary uveal melanoma Phase: Phase 3Trial ID: NCT07015190Treatment: DarovasertibStage: Primary uveal melanoma – the cancer must not have spread to other parts of the bodyUK locations: University College London Hospital and The Clatterbridge Cancer Centre, Liverpool What is this trial looking at? OptimUM-10 is investigating whether giving a drug called darovasertib before the usual treatment

Neoadjuvant Darovasertib in Primary Uveal Melanoma – NCT07015190 Read More »

Different Doses of BI-1607 in Combination With Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors – NCT04336241

This Phase 1 clinical trial is investigating a new type of immunotherapy called RP2 for people with advanced solid tumours, including metastatic uveal melanoma. RP2 is an engineered herpes simplex virus (HSV-1) designed to infect and destroy cancer cells while also stimulating the body’s immune system to recognise and attack the tumour. The treatment has

Different Doses of BI-1607 in Combination With Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors – NCT04336241 Read More »

ACTengine® IMA203/​IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/​or Refractory Solid Tumors (ACTengine) – NCT03686124

This Phase 1 clinical trial is investigating a personalised T-cell therapy called IMA203 (also known as anzutresgene autoleucel) for people with advanced solid tumours, including metastatic uveal melanoma. IMA203 is a type of immunotherapy designed to genetically modify a patient’s own immune cells (T cells) so they can better recognise and attack cancer cells carrying

ACTengine® IMA203/​IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/​or Refractory Solid Tumors (ACTengine) – NCT03686124 Read More »

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma (NBM-BMX-UM) – NCT07136181

This Phase 1/2 clinical trial is investigating a new targeted treatment called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body. NBM-BMX is designed to target a pathway involved in tumour growth and cancer cell survival, with researchers hoping it may help slow

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma (NBM-BMX-UM) – NCT07136181 Read More »

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/​11 Mutations or PRKC Fusions – NCT03947385

This Phase 1/2 clinical trial is investigating the safety and effectiveness of darovasertib (also known as IDE196) in people with advanced solid tumours, including metastatic uveal melanoma. Darovasertib is a targeted treatment designed to block a protein called PKC, which is abnormally activated in around 90% of uveal melanoma cases due to GNAQ or GNA11

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/​11 Mutations or PRKC Fusions – NCT03947385 Read More »

Adjuvant Tebentafusp in High Risk Ocular Melanoma (ATOM) – NCT06246149

This Phase 3 clinical trial, known as the ATOM study, is investigating whether a drug called tebentafusp can help prevent or delay the return of uveal melanoma in patients who are considered at high risk of their cancer spreading after treatment of the primary tumour. Tebentafusp is an immunotherapy drug that has already shown benefits

Adjuvant Tebentafusp in High Risk Ocular Melanoma (ATOM) – NCT06246149 Read More »

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors – NCT07070232

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors – NCT07070232 Read More »

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466

This early-phase clinical trial is testing a new treatment called brenetafusp (IMC-F106C) for adults with advanced cancers that test positive for a specific protein called PRAME. Brenetafusp is a type of immunotherapy known as an ImmTAC®, which is designed to help the immune system find and destroy cancer cells. To take part in the trial, patients must also

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466 Read More »

Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma – NCT06784648

This is an early-phase clinical trial testing a new drug called BI-1607 for people with melanoma that has spread or cannot be removed by surgery. The aim is to see whether combining BI-1607 with two existing treatments, ipilimumab and pembrolizumab, is safe and more effective than current options. BI-1607 is designed to help the body’s

Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma – NCT06784648 Read More »

Study of Roginolisib in UM Patients (OCULE-01) – NCT06717126

This Phase II study is being conducted at multiple centres to evaluate the effectiveness of a drug called Roginolisib in treating advanced or metastatic ocular/uveal melanoma. The study is open-label, meaning all participants will know they are receiving the treatment, and participants will be randomly assigned to different treatment groups to assess the anti-tumour activity

Study of Roginolisib in UM Patients (OCULE-01) – NCT06717126 Read More »